Attenuated effects of Jianpi Qushi herbs on patients receiving FOLFOX4 after colorectal cancer surgery: A meta-analysis

Shi, Qi; Li, Wen; Le, Qiqi; Chen, Wenting; Ren, Jianlin; Li, Qi; Hou, Fenggang

doi:10.1007/s11655-015-2437-2

Cited by 8 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The obstruction of the blood and blood vessels will lead to the loss of the healthy qi , and insufficient healthy qi will result in the imbalance of yin and yang . Moreover, long-term dietary disorders, weakness of the spleen and stomach, dysfunction of the internal organs, and the internal growth of evil toxins and eventually lead to blood stasis [ 15 , 16 ]. Chemotherapy is detrimental to the healthy qi and causes deficiency of the spleen.…”

Section: Discussionmentioning

confidence: 99%

Clinical Efficacy of Modified Yiwei Shengyang Decoction Combined with FOLFOX4 Chemotherapy Regimen in the Treatment of Advanced Gastric Cancer and Its Effect on Tumor Marker Levels

Miao

Liu

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. To study the clinical efficacy of modified Yiwei Shengyang decoction combined with FOLFOX4 chemotherapy regimen in the treatment of advanced gastric cancer and its effect on tumor marker levels. Methods. A total of 106 patients with advanced gastric cancer who were treated in our hospital from September 2019 to September 2021 were recruited and assigned via random number allocation to receive either FOLFOX4 chemotherapy (control group) or modified Yiwei Shengyang decoction plus FOLFOX4 chemotherapy (observation group). Outcome measures included clinical efficacy and tumor marker levels. Results. Modified Yiwei Shengyang decoction plus FOLFOX4 chemotherapy was associated with a significantly higher efficacy (86.79%, including 22 (41.51%) cases of complete response (CR), 24 (45.28%) cases of partial response (PR), 6 (11.32%) cases of stable disease (SD), and 1 (1.89%) case of progressive disease (PD)) compared to FOLFOX4 chemotherapy alone (47.16%, including 10 (18.87%) cases of CR, 15 (28.30%) cases of PR, 21 (39.62%) cases of SD, and 7 (13.21%) cases of PD) ( P < 0.05 ). There was no significant difference in the levels of CEA and CA19-9 between the two groups before treatment ( P > 0.05 ). Modified Yiwei Shengyang decoction plus FOLFOX4 chemotherapy resulted in significantly lower levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) (2.08 ± 0.47, 15.12 ± 6.74) compared to FOLFOX4 chemotherapy alone (5.46 ± 1.84, 31.82 ± 7.48) ( P < 0.05 ). Conclusion. Modified Yiwei Shengyang decoction plus FOLFOX4 chemotherapy regimen is effective in the treatment of advanced gastric cancer. It regulates the levels of various serum tumor markers in patients and controls the disease, so it is worthy of clinical application and promotion.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Efficacy of Modified Yiwei Shengyang Decoction Combined with FOLFOX4 Chemotherapy Regimen in the Treatment of Advanced Gastric Cancer and Its Effect on Tumor Marker Levels

Miao

Liu

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…Our further subgroup analysis reveal that TCM has a tendency to further reduce the risk of metastatic recurrence in elderly (no less than 60 years old) female patients, and has the same tendency in patients with rectal cancer, adenocarcinoma, poorly differentiation, stage III disease, comorbidities, or chemotherapy. We consider that may be related to the role of TCM in efficacy enhancing and toxicity reducing, improving immunity and quality of life [ 17 – 24 ].…”

Section: Discussionmentioning

confidence: 99%

Exploring the medication duration based on the effect of traditional Chinese medicine on postoperative stage I-III colorectal patients: a retrospective cohort study

Shi

Liu

et al. 2017

Oncotarget

Self Cite

View full text Add to dashboard Cite

PurposeTo clarify the effect of tradional Chinese medicine (TCM) on different stage patients and to explore medication duration based on survival analysis.Results523 and 294 patients were respectively in the TCM group and the control group. For all patients, 6-year disease-free survival (DFS) was 57.6% after TCM and 46.6% after non-TCM (p = 0.0006). 6-year DFS for patients with stage I disease in the TCM group was 79.5% compared with 89.1% in the control group (p = 0.65). For patients with stage II disease, 6-year DFS was 63.1% in the TCM group compared with 50.2% in the control group (p = 0.054), and for patients with stage III disease, it was 43.3% in the TCM group compared with 22.0% in the control group (p = 0.0000).Materials and MethodsData for patients with stage I-III disease between 2004 and 2013 were retrieved for this study, who underwent TCM after surgery were in the TCM group and the others were in the control group. Clinic appointments or phone were used to collect data by research assistants. Survival data were collected on Nov 2015 from the database, which is continuously updated by the researchers.ConclusionsTCM is associated with significantly improved disease-free survival, in particular for patients with stage III disease. Among of these, TCM is not necessary for patients with stage I disease, and postoperative patients with stage II disease should be recommended to take 2 years of TCM. For patients with stage III disease, adherence to medication of TCM during the 6-year follow-up is worthy of being recommended.

show abstract

“…In this study, we found that patients with stage I CRC on either side did not benefit from TCM, whereas subjects with stage II-III LSCRC or RSCC who were administered TCM exhibited a distinct advantage in decreasing the risk of recurrence and metastasis; however, this advantage was not statistically significant in subjects with stage II RSCC. We thought that the primary reasons why TCM improved DFS of CRC on both sides lie in the advantages of TCM in attenuating toxicity, improving immunity and quality of life and enhancing medication sensitivity in patients with tumors, which can prevent metastasis and extend survival[ 13 - 17 ].…”

Section: Discussionmentioning

confidence: 99%

Right- and left-sided colorectal cancers respond differently to traditional Chinese medicine

Liu¹,

Shi²,

Li³

et al. 2017

WJG

Self Cite

View full text Add to dashboard Cite

AIMTo explore the differences in the responses of left-sided colorectal cancer (LSCRC) and right-sided colon cancer (RSCC) to traditional Chinese medicine (TCM).METHODSPatients with postoperative stage I-III colorectal cancer (CRC) were enrolled and divided into the LSCRC with or without TCM and RSCC with or without TCM groups depending on the primary tumor side and TCM administration. Patients in the TCM group were given TCM for at least 6 mo. Our research adopted disease-free survival (DFS) as the primary endpoint. We applied a Cox proportional hazards regression model for the multivariate factor analysis using Stata 12.0 and SPSS 22.0 software for data analysis.RESULTSOf the 817 patients included in our study, 617 had LSCRC (TCM group, n = 404; Non-TCM group, n = 213), and 200 had RSCC (TCM group, n = 132; Non-TCM group, n = 68). The 6-year DFS for patients with LSCRC was 56.95% in the TCM group and 41.50% in the Non-TCM group (P = 0.000). For patients with RSCC, the 6-year DFS was 52.92% in the TCM group and 37.19% in the Non-TCM group (P = 0.003). Differences between LSCRC and RSCC were not statistically significant regardless of TCM ingestion.CONCLUSIONPatients with either LSCRC or RSCC and who took TCM experienced longer DFS; furthermore, patients with RSCC benefited more from TCM in DFS.

show abstract

Attenuated effects of Jianpi Qushi herbs on patients receiving FOLFOX4 after colorectal cancer surgery: A meta-analysis

Abstract: JPQS herbs can improve the quality of life for patients undergoing FOLFOX4 treatment after colorectal cancer surgery, relieve symptoms, and somewhat reduce the adverse effects of FOLFOX4 regimen.

Cited by 8 publications

References 12 publications

Clinical Efficacy of Modified Yiwei Shengyang Decoction Combined with FOLFOX4 Chemotherapy Regimen in the Treatment of Advanced Gastric Cancer and Its Effect on Tumor Marker Levels

Clinical Efficacy of Modified Yiwei Shengyang Decoction Combined with FOLFOX4 Chemotherapy Regimen in the Treatment of Advanced Gastric Cancer and Its Effect on Tumor Marker Levels

Exploring the medication duration based on the effect of traditional Chinese medicine on postoperative stage I-III colorectal patients: a retrospective cohort study

Right- and left-sided colorectal cancers respond differently to traditional Chinese medicine

Contact Info

Product

Resources

About